In Vivo CAR T-Cell Therapy Spurs 100% ORR in Phase I.

In vivo CAR T-cell therapy KLN-1010 achieved a 100% overall response rate in all 18 multiple myeloma patients in a phase I trial.

• Why it matters: This work addresses the need for effective treatments in multiple myeloma, as current options often leave residual disease. Demonstrating complete responses could significantly improve patient outcomes.
• What they did: The study involved 18 patients with multiple myeloma receiving the in vivo CAR T-cell therapy KLN-1010, with all patients responding and no minimal residual disease detected one month post-treatment.
• The result: The findings suggest that KLN-1010 may have strong clinical potential, as it induced complete responses in all evaluable patients, supporting further development of this therapy.